- The phase 3 IMMvent trial indicated that continuous treatment with risankizumab, an IL-23 inhibitor, is safe and superior to adalimumab in the treatment of moderate-to-severe psoriasis.
- Patients who were switched from adalimumab to risankizumab also showed superior benefit compared with those who continued adalimumab therapy.
Why this matters
- IL-23 plays key role in the pathogenesis and maintenance of plaque psoriasis.
- Intermediate and nonresponders to adalimumab should be considered for risankizumab therapy.
- Risankizumab resulted in significantly greater efficacy than adalimumab as measured by Psoriasis Area and Severity Index (PASI) 90, static Physician's Global Assessment clear or almost clear (sPGA 0/1), and Dermatology Life Quality Index (DLQI) scores, at weeks 16 and 44 (P<.001 for all>
- Week 16 PASI90 (72.4% vs 47.4%) and sPGA 0/1 (83.7% vs 60.2%).
- Week 44 PASI90 (66% vs 21.4%) and sPGA 0/1 (73.6% vs 33.9%).
- 605 patients were randomly assigned 1:1 to receive risankizumab or adalimumab for 16 weeks (part A).
- At week 16, patients with intermediate response to adalimumab (as measured by PASI) were randomly assigned 1:1 to receive risankizumab or continue adalimumab (part B).
- Funding: AbbVie, Inc. and Boehringer Ingelheim Pharmaceuticals.